会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Kinetic resolutions of chiral 2- and 3-substituted carboxylic acids
    • 手性2-取代和3-取代羧酸的动力学分辨率
    • US06562966B2
    • 2003-05-13
    • US09919371
    • 2001-07-31
    • Li DengJianfeng HangLiang Tang
    • Li DengJianfeng HangLiang Tang
    • C07D41312
    • C07D263/20C07B53/00C07B57/00C07B2200/07C07C51/00C07C51/487C07C67/12C07C227/34C07C269/06C07D317/36C07D401/14C07D453/02Y02P20/582C07C59/56C07C59/48C07C59/01C07C69/732C07C69/675C07C271/22
    • One aspect of the present invention relates to a method for the kinetic resolution of racemic and diastereomeric mixtures of chiral compounds. The critical elements of the method are: a non-racemic chiral tertiary-amine-containing catalyst; a racemic or diastereomeric mixture of a chiral substrate, e.g., a cyclic carbonate or cyclic carbamate; and a nucleophile, e.g., an alcohol, amine or thiol. A preferred embodiment of the present invention relates to a method for achieving the kinetic resolution of racemic and diastereomeric mixtures of derivatives of &agr;- and &bgr;-amino, hydroxy, and thio carboxylic acids. In certain embodiments, the methods of the present invention achieve dynamic kinetic resolution of a racemic or diastereomeric mixture of a substrate, i.e., a kinetic resolution wherein the yield of the resolved enantiomer or diastereomer, respectively, exceeds the amount present in the original mixture due to the in situ equilibration of the enantiomers or diastereomers under the reaction conditions prior to the resolution step.
    • 本发明的一个方面涉及手性化合物的外消旋和非对映体混合物的动力学拆分方法。 该方法的关键元素是:非外消旋手性叔胺催化剂; 手性底物,例如环状碳酸酯或环状氨基甲酸酯的外消旋或非对映体混合物; 和亲核试剂,例如醇,胺或硫醇。 本发明的优选实施方案涉及一种实现α和β-氨基,羟基和硫代羧酸的衍生物的外消旋和非对映体混合物的动力学拆分的方法。 在某些实施方案中,本发明的方法实现了底物的外消旋或非对映体混合物的动态动力学拆分,即动力学拆分,其中分辨的对映异构体或非对映体的产率分别超过原始混合物中存在的量 涉及在分离步骤之前的反应条件下对映异构体或非对映异构体的原位平衡。
    • 7. 发明授权
    • Cyclic oxyguanidine pyrazinones as protease inhibitors
    • 环氧乙酰吡嗪酮作为蛋白酶抑制剂
    • US06476016B2
    • 2002-11-05
    • US09905883
    • 2001-07-17
    • Aihua WangBruce Edward TomczukTianbao LuRichard M. SollJohn Curtis SpurlinoRoger Francis Bone
    • Aihua WangBruce Edward TomczukTianbao LuRichard M. SollJohn Curtis SpurlinoRoger Francis Bone
    • C07D41312
    • C07D413/12C07D413/14
    • Cyclic oxyguanidine pyrazinone compounds are described, including compounds of the Formula I: wherein R3, R4, R5, W, and A are as set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. Compositions for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation are described. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.
    • 描述了环状氧基胍吡嗪酮化合物,包括式I的化合物:其中R 3,R 4,R 5,W和A如说明书中所述,以及其水合物,溶剂合物或其药学上可接受的盐。 本发明的化合物是蛋白酶的有效抑制剂,特别是胰蛋白酶样丝氨酸蛋白酶,如胰凝乳蛋白酶,胰蛋白酶,凝血酶,纤溶酶和因子Xa。 某些化合物通过直接,选择性抑制凝血酶表现出抗血栓形成活性。 描述了抑制血小板损失,抑制血小板聚集体形成,抑制纤维蛋白形成,抑制血栓形成和抑制栓塞形成的组合物。 本发明化合物的其它用途是作为凝血剂或者物理上连接于用于血液收集,血液循环和血液储存(例如导管,血液透析机,采血注射器和管)中使用的装置的制造中使用的材料的抗凝剂, 血线和支架。 另外,化合物可以被可检测地标记并用于血栓的体内成像。
    • 8. 发明授权
    • Process for preparing &bgr;-hydroxycarbamates and their conversion to oxazolidinones
    • 制备β-羟基氨基甲酸酯及其转化为恶唑烷酮的方法
    • US06372911B1
    • 2002-04-16
    • US09482799
    • 2000-01-13
    • Nancy BartaRobert D. LarsenDaniel R. SidlerSteven A. Weissman
    • Nancy BartaRobert D. LarsenDaniel R. SidlerSteven A. Weissman
    • C07D41312
    • C07D413/12C07C271/16C07D211/18C07D263/38
    • A process for preparing a &bgr;-hydroxy carbamate product is disclosed. The process comprises reacting an olefin compound containing at least one carbon-carbon double bond with a carbamate in an aqueous solvent and in the presence of a base, an osmium catalyst, a co-oxidant selected from a halohydantoin, a haloisocyanuric acid, and an alkali metal salt of a haloisocyanuric acid, and optionally an asymmetric ligand, to form a reaction mixture containing the &bgr;-hydroxy carbamate product. The process optionally further comprises treating the &bgr;-hydroxy carbamate product with additional base to form an oxazolidinone. The oxazolidinones are useful as chiral auxiliary agents and as intermediates for the formation of pharmaceutically active substances such as alpha 1 a adrenergic receptor antagonists. A process for preparing nitrogen-functionalized derivatives of the oxazolidinones is also disclosed.
    • 公开了一种制备β-羟基氨基甲酸酯产物的方法。 该方法包括使含有至少一个碳 - 碳双键的烯烃化合物与氨基甲酸酯在水溶剂中反应,并在碱,锇催化剂,选自卤代乙内酰脲,卤代异氰脲酸和 卤代异氰尿酸的碱金属盐和任选的不对称配体,以形成含有β-羟基氨基甲酸酯产物的反应混合物。 该方法任选地还包括用另外的碱处理β-羟基氨基甲酸酯产物以形成恶唑烷酮。 恶唑烷酮可用作手性助剂,也可用作形成药物活性物质如α1肾上腺素能受体拮抗剂的中间体。 还公开了制备恶唑烷酮的氮官能化衍生物的方法。
    • 10. 发明授权
    • Neurotrophin production secretion promoting agent
    • 神经营养蛋白生成分泌促进剂
    • US06605629B1
    • 2003-08-12
    • US09868304
    • 2001-06-29
    • Yu MomoseKatsuhito Murase
    • Yu MomoseKatsuhito Murase
    • C07D41312
    • C07D263/34C07D231/12C07D233/56C07D249/08C07D263/38C07D263/46C07D263/48C07D277/32C07D277/40C07D277/54C07D413/04C07D413/12C07D417/04C07D417/14
    • A neurotrophin production/secretion promoting agent which comprises an azole derivative of the formula: wherein R1 represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; X represents oxygen atom, sulfur atom, or nitrogen atom which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof; which is useful as an agent for preventing or treating neuropathy.
    • 一种神经营养因子产生/分泌促进剂,其包含下式的唑衍生物:其中R1表示卤素原子,可任意取代的杂环基,可任选被取代的羟基,可任选被取代的硫醇基, 或可任选被取代的氨基; A表示可任选被取代的酰基,可任选被取代的杂环基,可任意取代的羟基或可任意被酯化或酰胺化的羧基; B表示可任选被取代的芳族基团; X表示可任选被取代的氧原子,硫原子或氮原子; Y表示二价烃基或杂环基,或其盐; 其可用作预防或治疗神经病的药剂。